AAV Vector Dual Gene Expression for GM2 Gangliosidoses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for GM2 gangliosidoses, such as Tay-Sach's and Sandhoff diseases, lack effective therapies, with existing gene therapy approaches limited by the need for direct administration to the CNS and challenges in expressing both β-hexosaminidase A (HexA) and β-hexosaminidase B (HexB) subunits due to vector size constraints and inflammation contributing to disease progression.
Innovation Solution
Development of nucleic acid constructs containing both HexA and HexB encoding elements in a single AAV vector, utilizing a self-cleaving P2A peptide linker to enable simultaneous expression of both subunits, combined with anti-inflammatory agents like indomethacin and ITF2357, for systemic administration to enhance HexA enzyme activity and reduce inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If both HEXA and HEXB genes are delivered using separate viral vectors, then both subunits can be expressed, but the treatment complexity increases and delivery to the CNS becomes more difficult
Solution Approach 1:
The patent combines both HEXA and HEXB coding sequences into a single nucleic acid construct that can be delivered by one viral vector. The construct uses a single promoter to drive expression of both genes, with appropriate spacing and orientation to ensure both subunits are produced and assembled into functional HexA enzyme complexes.
Solution Approach 2:
The single nucleic acid construct serves multiple functions: it delivers both HEXA and HEXB genes, uses a single promoter for dual gene expression, and enables co-expression of both subunits from one therapeutic agent, simplifying the overall gene therapy approach.
2Device complexity
If a single viral vector delivers both HEXA and HEXB genes, then treatment simplicity increases, but the vector size constraint may prevent successful packaging
Solution Approach 1:
The construct is designed with careful segmentation of the dual gene arrangement, placing HEXA and HEXB coding sequences in specific orientations and positions within the viral genome to optimize packaging efficiency while maintaining expression of both subunits.
3Ease of operation
If gene therapy is administered systemically, then delivery to peripheral tissues is improved, but CNS targeting becomes less efficient
Solution Approach 1:
The patent employs AAV9 as the viral vector, which serves as an intermediary that can be administered systemically but has demonstrated ability to cross the blood-brain barrier and deliver genetic material to the CNS. The vector acts as a mediator between systemic circulation and central nervous system delivery.
4Quantity of substance
If inflammation is allowed to proceed naturally, then the immune response clears GM2 gangliosides, but neuronal damage and disease progression worsen
Solution Approach 1:
The patent leverages the inflammatory response by using anti-inflammatory medications to modulate it, converting the harmful uncontrolled inflammation into a beneficial controlled response that clears GM2 gangliosides while protecting neurons from damage through concurrent anti-inflammatory therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach significantly increases survival and motor activity in mouse models, reduces GM2 ganglioside storage, and demonstrates the potential for a synergistic gene and drug therapy in delaying disease progression by achieving therapeutic levels of HexA activity and mitigating inflammatory responses.
Implementation Method 1
a nucleotide sequence encoding a self-cleaving peptide that links the HEXB gene and the HEXA gene
Data Source
AI summary
Disclosed are novel gene therapy constructs containing both HEXA and HEXB genes to treat GM2 gangliosidoses, including Sandhoff disease and Tay-Sach's disease. Also described are co-treatments using chaperone and anti-inflammatory agents to enhance the effects of gene therapy.